Zai Lab Shares Rise 7.3% on Positive Phase 1 Trial Data
Zai Lab said it reported positive data from a Phase 1 trial evaluating its small cell lung cancer treatment. Shares rose 7.3% in premarket trading to $23.65.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.